Skip to main content

Ysios Capital Partners participates in a capital increase of Endosense

By 2 de September de 2009November 18th, 2020No Comments
< Back to news

Ysios Capital Partners participates in a capital increase of Endosense

The capital risk company Ysios Capital Partners, located at the Barcelona Science Park, has participated in a 25 million Euro capital increase that has been carried out by the company Endosense. This company is specialised in the development of medical devices focused on improving the efficacy and safety of the use of catheters in the treatment of cardiac arrhythmia ablations. This operation is one of the most relevant financing rounds in medical technology carried out in Europe in 2009.

Edmond de Rothschild Investment Partners has led this second financing round of the company, in which, in addition to Ysios Capital Partners, the companies Neomed, GIMV, Venture Incubator AG, Sectorial Asset Management and Initiative Capital Romandie have taken part. The capital obtained will be mainly aimed at the European commercialisation of Endosense’s primary product: the new generation TactiCath© catheter, as well as at inititating the product’s approval process in the United States.

TactiCath© has been granted approval with the CE mark and has been developed and tested in preclinical and clinical studies. It is the first and only catheter for cardiac ablation that incorporates strength sensors that provide the clinician with real time information on the strength applied in an intuitive manner. This device has the potential to improve the efficacy and safety of catheters in ablation treatment of cardiac arrhythmia-related pathologies, a technology which eliminates the need to perform open heart surgery or apply therapies that require long-term drug use.